Ponezumab in mild-to-moderate Alzheimer's disease: Randomized phase II PET-PIB study.

Alzheimers Dement (N Y) · 2017 · PMC5651442 · PMID 29067345

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Furthermore, solanezumab that also recognizes soluble, monomeric amyloid has showed a trend in three successive phase III pivotal trials for modest clinical meaningful improvement albeit nonsignificant on the primary end point.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.